Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

REMS Must Be Designed With Input From Doctors, Kaiser Tells FDA In Petition

Executive Summary

Kaiser Permanente is pressing FDA to open up the process for creating Risk Evaluation and Mitigation Strategies to a broader audience

You may also be interested in...



FDA Seeks To Write MedGuides Outside REMS Process

FDA is searching for a way out of imposing a REMS when only a medication guide is required

FDA Seeks To Write MedGuides Outside REMS Process

FDA is searching for a way out of imposing a REMS when only a medication guide is required

FDA Seeks To Write MedGuides Outside REMS Process

Agency advice on REMS evolves as FDA gains experience with the program, OSE Director Dal Pan says at DIA.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS051854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel